Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Prevention of Meningococcal Infection Clinical Trial

Official title:
A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine

Status Completed

Clinical Trial Summary

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Meningococcal Infections
Prevention of Meningococcal Infection

Clinical Trial Details

NCT number	NCT00310674
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 3
Start date	September 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00311415` - Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children	Phase 3
Completed	`NCT00310687` - Persistence of Immune Response After Vaccination With MCC	Phase 4
Completed	`NCT00310700` - Kinetics of B Cell Response in Infants Menjugate Vaccination	Phase 4
Completed	`NCT00316654` - Persistence of Antibody Response to N. Meningitidis Group C in Children	Phase 4
Completed	`NCT00310713` - Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine	Phase 4